Muscle tissue regeneration using muscle fiber fragments

Patent metadata

Field	Value
Publication number	US-9962466-B2
Application number	US-201615159219-A
Country	US
Kind code	B2
Filing date	May 19, 2016
Priority date	Aug 17, 2011
Publication date	May 8, 2018
Grant date	May 8, 2018

Abstract

The invention is directed to methods and compositions for obtaining uniform sized muscle fiber fragments for transplantation. These muscle fiber fragments are able to reconstitute into long fibers that are oriented along native muscle. The implanted muscle cells integrate with native vascular and neural network, as confirmed by histology and immunohistochemistry. This invention is particularly advantageous because autologous muscle can be harvested from a donor site, processed and injected into target sites in the operating room. The fragmented muscle fibers can be readily integrated within the host.

First claim

What is claimed is:

1. A method of preparing a muscle regenerating composition comprising:
extracting muscle tissue from a donor site,
disaggregating muscle fibers from the extracted tissue, and
fragmenting the disaggregated muscle fibers into fiber fragments which comprise the muscle regenerating composition while retaining viable satellite cells associated with at least some of the fragments, wherein said fragments exhibit cell wall rupture and have an average size of less than 100 μm, and
seeding the composition onto a scaffold and/or delivering the composition to a muscle defect target site,
wherein the composition is capable of reconstructing elongated muscle fibers from the fragments and orienting in alignment with native muscle fibers when implanted in a target muscle site.

2. The method of claim 1 , wherein the aspect ratio of the muscle fiber fragments is between 2:1 and 1:1.

3. The method of claim 1 , wherein the step of extracting muscle tissue comprises extracting autologous muscle tissue.

4. The method of claim 1 , wherein the step of disaggregating muscle fibers from tissue comprises disaggregating the muscle fibers with an enzyme.

5. The method of claim 4 , wherein the enzyme is Collagenase type I.

6. The method of claim 1 , wherein the fragmentation is mechanical agitation.

7. The method of claim 6 , wherein the fragmenting step further comprises filtering the fragmented fiber fragments to an average size of less than 100 μm.

8. The method of claim 1 , wherein at least 75% of the muscle fiber fragments exhibit cell wall rupture.

9. The method of claim 1 wherein the method further comprises delivering the composition to a muscle defect target site.

10. The method of claim 9 wherein the method further comprises suspending the composition in a physiologically compatible fluid and injecting the composition into the muscle defect target site.

11. The method of claim 10 , wherein the step of injecting the composition occurs within 10 hours of the step of extracting the muscle tissue from a donor site.

12. The method of claim 1 wherein the method further comprises seeding the composition onto a scaffold and implanting the seeded scaffold at a muscle defect target site.

13. The method of claim 12 wherein the method further comprises culturing the scaffold-supported fragments in vitro and then delivering the scaffold to a muscle defect target site.

14. The method of claim 13 , wherein the scaffold is an injectable scaffold selected from collagen gel, fibrin gel, alginate gel, or UV-induced crosslinkable gel system.

15. The method of claim 13 , wherein the scaffold is an implantable scaffold comprising a polymeric or organic matrix.

16. The method of claim 15 wherein the polymeric matrix comprises at least one polymer selected from the group of (a) a natural polymer selected from the group consisting of collagen and elastin; and (b) a synthetic polymer selected from the group consisting of polycaprolactone (PCL), poly(D,L-lactide-co-glycolide) (PLGA), polylactide (PLA), poly(lactide-co-captrolactone) (PLCL), and combinations thereof.

17. The method of claim 16 , wherein the matrix comprises an electrospun fiber matrix formed by a combination of at least one natural polymer and at least one synthetic polymer.

18. The method of claim 17 , wherein the matrix comprises collagen and polycaprolactone (PCL).

19. The method of claim 12 , wherein the seeded scaffold further comprises a bone morphogenic protein (BMP), a RUNX-2 protein, a LIM mineralization protein, a fibroblast growth factor, a platelet derived growth factor, an epidermal growth factor, an insulin-like growth factor, a transforming growth factor-a, a transforming growth factor-β, a nerve growth factor (NGF), a brain-derived neurotrophic factor (BDNF), a neuregulin (NRG), agrin, or a combination thereof.

20. The method of claim 1 wherein the method further comprises co-administering the composition with an adjuvant.

21. The method of claim 20 wherein the adjuvant comprises at least one agent selected from the group of stem cells, muscle progenitor cells and growth factors.

22. The method of claim 21 wherein the adjuvant comprises at least one growth factor selected from the group of bone morphogenic protein (BMP), a RUNX-2 protein, a LIM mineralization protein, a fibroblast growth factor, a platelet derived growth factor, an epidermal growth factor, an insulin-like growth factor, a transforming growth factor-a, a transforming growth factor-β, a nerve growth factor (NGF), a brain-derived neurotrophic factor (BDNF), a neuregulin (NRG), and agrin.

23. The method of claim 20 wherein the adjuvant comprises muscle progenitor cells.

24. The method of claim 1 wherein the method further comprises injecting the muscle generating composition at a target site proximal to a subject's urinary sphincter to treat urinary incontinence.

Assignees

• Univ Wake Forest Health Sciences

Inventors

• Atala Anthony
• Yoo James
• Ko In Kap

Classifications

• A61L27/3604 Primary

  characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel · CPC title

• C12N2513/00

  3D culture · CPC title

• C12N2533/30

  Synthetic polymers · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61L2430/30

  for muscle reconstruction · CPC title